Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: systematic review

Abstract

Background: Accurate seroprevalence estimates of SARS-CoV-2 in different populations could help gauge the true magnitude and spread of the infection seroprevalence. Reported estimates have varied greatly, but many have derived from biased samples, and inadequate testing methods. Objective: To estimate the range of valid seroprevalence rates of SARS-CoV-2 in different populations, and compare these seroprevalence estimates with the cumulative cases seen in the same population. Methods: We searched PubMed, Embase, the Cochrane COVID-19 trials, and Europe-PMC for published studies and pre-prints from January 2020 to 25 May 2020 that reported anti-SARS-CoV-2 IgG, IgM and/or IgA antibodies for serosurveys of either the general community or of defined sub-populations, such healthcare workers and other organizations. Results: Of the 837 studies identified, 49 were assessed and 14 were includable. Included studies represented 10 countries and 100,557 subjects: 9 from randomly selected populations, 2 from healthcare workers, 2 from industry populations, and 1of parturient women. The seroprevalence proportions in 10 studies ranged between 1%-10%, and 2 study estimates under 1%, and 2 over 10% - from the notably hard-hit regions of Gangelt in Germany and from Northwest Iran. The two studies in healthcare workers, in Italy and Spain, had seroprevalence rates at higher range of estimates, with the Barcelona hospitals having a higher rate than the Spanish national survey. For only one study was the seroprevalence estimate higher than the cumulative incidence, though these were proximate for several studies. In five studies, the seroprevalence was similar to the cumulative case numbers in the same population. For seropositive cases not previously detected as COVID-19 cases, the majority had prior COVID-like symptoms. Conclusion: The seroprevalence of SARS-CoV-2 mostly less than 10% with the level of infection lower in the general community, suggesting levels well below herd immunity. The similarity of seroprevalence and reported cases is several studies, and high symptom rates in seropositive cases suggest that gaps between seroprevalence rates and reported cases are likely due to undertesting of symptomatic people.

Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications

“…To provide more accurate assessments of the spread of COVID-19, researchers have conducted seroprevalence studies in numerous locations [7,8]. Such studies analyze samples of serum to detect antibodies in those infected with SARS-CoV-2, the virus that causes COVID-19.…”

COVID-19 herd immunity: where are we?

“…Population immunity is typically estimated through cross-sectional surveys of representative samples using serological tests that measure humoral immunity. Surveys performed in countries affected early during the COVID-19 epidemic, such as Spain and Italy, suggest that nationwide prevalence of antibodies varies between 1 and 10%, with peaks around 10-15% in heavily affected urban areas 4 . Interestingly, this is consistent with earlier predictions made by mathematical models, using death counts reported in national statistics and estimates of the infection fatality ratio, that is, the probability of death given infection 1,5 .…”

COVID-19: Is herd immunity the only option for fragile Yemen?

“…Seroprevalence studies will give a better understanding on the COVID-19 transmission trajectory in Yemen. Seroprevalence studies on COVID-19 in other countries have always indicated much higher infections than reported ( Byambasuren et al, 2020 ). For example, a study in India indicated that the number of infections was 130 times higher than the reported number, during the study period ( Murhekar et al, 2020 ).…”